A retrospective analysis of adverse events from ciclopirox 8% solution, efinaconazole 10% solution and tavaborole 5% solution with topical onychomycosis medications reported to the USFDA
Latest Information Update: 08 Jun 2021
At a glance
- Drugs Ciclopirox (Primary) ; Efinaconazole (Primary) ; Tavaborole (Primary)
- Indications Onychomycosis
- Focus Adverse reactions
- 08 Jun 2021 New trial record